31 related articles for article (PubMed ID: 8991237)
1. Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.
Carazo S; Billard MN; Boutin A; De Serres G
BMC Infect Dis; 2020 Mar; 20(1):251. PubMed ID: 32223757
[TBL] [Abstract][Full Text] [Related]
2. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.
Collaborative Group for Studies of Yellow Fever Vaccine
Mem Inst Oswaldo Cruz; 2015 Sep; 110(6):771-80. PubMed ID: 26517656
[TBL] [Abstract][Full Text] [Related]
3. [A new combined vaccine against yellow fever and measles in infants aged 6 to 24 months in Mali].
Soula G; Sylla A; Pichard E; Kodio B; Bentejac MC; Teulières L; Saliou P
Bull Soc Pathol Exot; 1991; 84(5 Pt 5):885-97. PubMed ID: 1819436
[TBL] [Abstract][Full Text] [Related]
4. [The combined measles-yellow fever vaccination in African infants aged 6 to 10 months].
Mouchon D; Pignon D; Vicens R; Tu-Ha-Thanh ; Tekaia F; Teulières L; Garrigue G
Bull Soc Pathol Exot; 1990; 83(4):537-51. PubMed ID: 2286007
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
6. Study of combined vaccination against yellow fever and measles in infants from six to nine months.
Lhuillier M; Mazzariol MJ; Zadi S; Le Cam N; Bentejac MC; Adamowicz L; Marie FN; Fritzell B
J Biol Stand; 1989 Jan; 17(1):9-15. PubMed ID: 2537830
[TBL] [Abstract][Full Text] [Related]
7. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
Ogunmekan DA; Harry TO
Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
[TBL] [Abstract][Full Text] [Related]
8. Field trial of combined yellow fever and measles vaccines among children in Nigeria.
Adu FD; Omotade OO; Oyedele OI; Ikusika O; Odemuyiwa SO; Onoja AL
East Afr Med J; 1996 Sep; 73(9):579-82. PubMed ID: 8991237
[TBL] [Abstract][Full Text] [Related]
9. Stability of yellow fever vaccine.
Monath TP
Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
[TBL] [Abstract][Full Text] [Related]
10. [Reemergence of yellow fever in West Africa: lessons from the past, advocacy for a control program].
Moreau JP; Girault G; Dramé I; Perraut R
Bull Soc Pathol Exot; 1999 Dec; 92(5):333-6. PubMed ID: 10690471
[TBL] [Abstract][Full Text] [Related]
11. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
Barrett AD; Teuwen DE
Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
[TBL] [Abstract][Full Text] [Related]
12. The relationship between dose and response of standard measles vaccines.
Diaz-Ortega JL; Forsey T; Clements CJ; Milstien J
Biologicals; 1994 Mar; 22(1):35-44. PubMed ID: 8068312
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
